Study Evaluating Enbrel in Patients With Rheumatoid Arthritis

Wyeth is now a wholly owned subsidiary of Pfizer1,500 enrolled

Overview

The purpose of this study is to investigate the incidence of adverse events for patients with rheumatoid arthritis treated with Enbrel under usual care settings. In addition, differences in injection site reactions based on whether health care professionals or patients administer Enbrel will be assessed and evaluated.

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

Rheumatoid Arthritis

Interventions

EnbrelDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Proven diagnosis of rheumatoid arthritis Exclusion Criteria: * Contraindications according to Summary of Product Characteristic (SmPC)of Enbrel® the following points will prevent or restrict participation: * Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel® * Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localized infections * Patients with sepsis or risk of sepsis should not be treated

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.